v3.25.3
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
9 Months Ended
Sep. 30, 2025
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of research and development expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended September 30, 

​

Nine months ended September 30, 

​

​

2025

    

2024

    

2025

    

2024

External clinical development expenses

​

$

1,645,882

​

$

687,666

​

$

4,980,796

​

$

1,450,903

Personnel related and stock-based compensation

​

 

464,008

​

 

253,739

​

 

1,151,498

​

 

726,358

Other research and development expenses

​

 

171,284

​

 

138,215

​

 

573,604

​

 

375,160

Total research and development expenses

​

$

2,281,174

​

$

1,079,620

​

$

6,705,898

​

$

2,552,421